10-Q: Haemonetics Reports Q2 2025 Results: Revenue Growth Driven by Hospital Segment, Earnings Mixed

Haemonetics Corporation's second quarter of fiscal year 2025 shows revenue growth driven by the Hospital segment, but mixed results in profitability and increased operating expenses.

Summary

• Haemonetics Corporation reported a net revenue of $345.5 million for the three months ended September 28, 2024, an 8.6% increase compared to the same period last year.
• The company's gross profit for the quarter was $187.4 million, a 9.9% increase year-over-year.
• Operating expenses totaled $135.7 million, a slight increase of 0.4% compared to the previous year.
• Operating income for the quarter was $51.7 million, a significant 46.4% increase from the prior year.
• Net income for the quarter was $33.8 million, or $0.66 per diluted share, compared to $24.9 million, or $0.48 per diluted share, in the same period last year.
• For the six months ended September 28, 2024, net revenue was $681.7 million, an 8.3% increase year-over-year.
• The company's gross profit for the six months was $362.4 million, a 7.3% increase year-over-year.
• Operating expenses for the six months totaled $270.9 million, an 8.9% increase compared to the previous year.
• Operating income for the six months was $91.5 million, a 2.8% increase from the prior year.
• Net income for the six months was $72.2 million, or $1.40 per diluted share, compared to $66.0 million, or $1.28 per diluted share, in the same period last year.
• The Hospital segment showed strong revenue growth, while the Plasma and Blood Center segments experienced declines.
• The company completed the acquisition of Attune Medical on April 1, 2024, and OpSens Inc. on December 12, 2023.
• Haemonetics issued $700 million in convertible senior notes due 2029 and repurchased $200 million of its 2026 notes.
• The company also entered into an accelerated share repurchase agreement to buy back $75 million of its common stock.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is positive, particularly in the Hospital segment, there are concerns about declining performance in the Plasma and Blood Center segments, increased operating expenses, and the impact of recent acquisitions. The company's strategic moves, such as acquisitions and debt management, are positive, but the overall sentiment is cautiously optimistic due to the mixed financial results.

Positives

• The Hospital segment demonstrated strong revenue growth, indicating successful expansion and market penetration.
• The company's operating income increased significantly in the three months ended September 28, 2024, showing improved profitability.
• Strategic acquisitions of Attune Medical and OpSens Inc. are expected to drive future growth and expand the company's product portfolio.
• The issuance of convertible senior notes and the repurchase of existing notes have improved the company's capital structure.
• The accelerated share repurchase program demonstrates confidence in the company's future prospects and commitment to shareholder value.

Negatives

• The Plasma segment experienced a revenue decrease of 3.0% in the three months and 2.8% in the six months ended September 28, 2024, primarily due to lower sales volumes in North America.
• The Blood Center segment also saw a revenue decrease of 1.6% in the three months and 2.9% in the six months ended September 28, 2024, driven by declines in the Whole Blood business.
• Operating expenses increased by 8.9% for the six months ended September 28, 2024, impacting overall profitability.
• Interest and other expenses increased significantly in the three months ended September 28, 2024, due to new debt issuance.
• The company's effective tax rate increased for the three months ended September 28, 2024, due to the jurisdictional mix of earnings and non-deductible acquisition-related expenses.

Risks

• The company faces risks related to demand and market acceptance of new and existing products.
• There are potential risks associated with product quality, safety, and recalls.
• Security breaches of information technology systems or products could disrupt business operations.
• The company may not realize the expected strategic benefits from completed acquisitions.
• Pricing pressures from healthcare cost containment trends could impact revenue.
• Disruptions in the supply chain for raw materials and components could affect manufacturing.
• The company faces risks related to compliance with regulatory requirements.
• Geopolitical and economic conditions in various regions could impact business operations.
• Foreign currency fluctuations and interest rate changes could affect financial results.
• The company is subject to product liability and other litigation claims.

Future Outlook

The company expects to incur aggregate charges between $85.0 million and $90.0 million by the end of fiscal 2025 under the Operational Excellence Program. The company anticipates sales of approximately $100.0 million to CSL in fiscal 2025. The company intends to use the remaining proceeds from the 2029 Notes for future cash requirements, which may include additional repurchases of the 2026 Notes or the repayment at maturity of the 2026 Notes.

Management Comments

• Management uses non-GAAP financial measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results.
• Management measures and evaluates the operating segments based on operating income.
• Management excludes certain corporate expenses from segment operating income.
• Management measures and evaluates the company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year.

Industry Context

The company's performance is influenced by trends in the healthcare industry, including cost containment pressures and consolidation among healthcare providers. The acquisitions of Attune Medical and OpSens Inc. reflect a strategic move to expand into high-growth areas within the hospital market, particularly in interventional cardiology and electrophysiology. The company's focus on innovation and technology is aligned with the broader industry trend of adopting advanced medical solutions to improve patient care and efficiency.

Comparison to Industry Standards

• Haemonetics' revenue growth of 8.3% year-over-year for the six months ended September 28, 2024, is a solid performance in the medical device industry, but it is important to compare this to specific competitors in the blood and plasma technology space.
• Companies like Terumo BCT and Fresenius Kabi are major players in blood component technology, and their growth rates and profitability should be compared to Haemonetics to assess relative performance.
• In the interventional cardiology market, competitors like Abbott and Boston Scientific have established positions, and Haemonetics' acquisition of OpSens is a move to compete in this space.
• The company's operating margin of 13.4% for the six months ended September 28, 2024, should be benchmarked against industry averages to determine if it is competitive.
• The company's debt levels and leverage ratios should be compared to industry standards to assess financial health and risk.
• The company's inventory turnover of 1.4 for the six months ended September 28, 2024, is lower than the 1.7 in the previous year, which may indicate a need for improved inventory management.

Legal Proceedings

• The company is involved in a legal proceeding related to the Illinois Biometric Information Privacy Act (BIPA), which has been settled with a payment of $8.7 million.
• The company is also involved in a patent infringement lawsuit filed by Koninklijke Philips N.V. and IP2IPO Innovations, Ltd. against OpSens and Haemonetics, which the company plans to vigorously defend against.

Stakeholder Impact

• Shareholders will be impacted by the share repurchase program and the company's financial performance.
• Employees may be impacted by restructuring programs and changes in headcount due to acquisitions.
• Customers will benefit from the company's expanded product portfolio and innovative solutions.
• Suppliers may be impacted by changes in the company's supply chain and sourcing strategies.
• Creditors will be impacted by the company's debt management and capital structure.

Next Steps

• The company will continue to integrate the acquired businesses of Attune Medical and OpSens Inc.
• The company will monitor the performance of the Plasma and Blood Center segments and implement strategies to improve their performance.
• The company will manage its debt obligations and capital structure.
• The company will continue to execute its share repurchase program.
• The company will continue to implement its global enterprise resource planning (ERP) system.

Key Dates

Keywords

Haemonetics, Medical Technology, Plasma, Blood Center, Hospital, Acquisition, Convertible Notes, Share Repurchase, Financial Results, Operating Income, Revenue Growth, Healthcare